Randomized phase II study of paclitaxel with or without the anti-IGF-IR antibody cixutumumab (IMC-A12) as second-line treatment for patients with metastatic esophageal or GE junction cancer

Authors

• S J. Cohen

Publication/Presentation Date

5-2014

Volume

32

Issue

15

Published In/Presented At

DOI: 10.1200/jco.2014.32.15_suppl.4020

Disciplines

Medicine and Health Sciences

Department(s)

Hematology-Medical Oncology Division

Document Type

Article